Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDCVE:EMHNYSE:MRPNYSEAMERICAN:PZGNYSE:REN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$174.07+0.6%$167.48$111.09▼$183.00$10.58B0.38500,084 shs157,816 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsMRPMillrose Properties$28.03-2.9%$27.40$19.00▼$28.99$4.79BN/A976,166 shs714,096 shsPZGParamount Gold Nevada$0.72+6.3%$0.54$0.31▼$0.73$48.41M1.13197,025 shs227,013 shsRENRESOLUTE ENERGY/SH NEW$30.91$0.00$24.60▼$39.28$715.88M3.2305,448 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.64%+0.06%-1.47%+15.33%+27.03%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%MRPMillrose Properties+1.23%+3.62%+4.48%+12.36%+2,889,999,900.00%PZGParamount Gold Nevada+4.23%+12.56%+14.83%+83.41%+102.24%RENRESOLUTE ENERGY/SH NEW0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.5544 of 5 stars4.53.00.00.02.21.70.6EMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMRPMillrose PropertiesN/AN/AN/AN/AN/AN/AN/AN/APZGParamount Gold Nevada0.2423 of 5 stars0.05.00.00.00.00.00.0RENRESOLUTE ENERGY/SH NEWN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$220.6726.77% UpsideEMHEmerald Health Therapeutics 0.00N/AN/AN/AMRPMillrose Properties 3.00Buy$30.759.70% UpsidePZGParamount Gold Nevada 0.00N/AN/AN/ARENRESOLUTE ENERGY/SH NEW 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ASND, REN, EMH, PZG, and MRP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/15/2025MRPMillrose PropertiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $31.505/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M27.04N/AN/A($1.88) per share-92.59EMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64MRPMillrose PropertiesN/AN/AN/AN/AN/AN/APZGParamount Gold NevadaN/AN/AN/AN/A$0.60 per shareN/ARENRESOLUTE ENERGY/SH NEW$303.48M2.36$4.48 per share6.90($3.31) per share-9.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A725.29N/A-93.22%N/A-33.29%9/2/2025 (Estimated)EMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AMRPMillrose Properties-$246.22MN/A0.00∞N/AN/AN/AN/AN/APZGParamount Gold Nevada-$8.06M-$0.12N/A∞N/AN/A-24.35%-16.19%N/ARENRESOLUTE ENERGY/SH NEW-$1.23MN/A41.61∞N/A-10.10%-22.38%2.45%N/ALatest ASND, REN, EMH, PZG, and MRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRPMillrose PropertiesN/A$0.39N/A$0.39N/A$82.70 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AMRPMillrose Properties$1.525.42%N/AN/AN/APZGParamount Gold NevadaN/AN/AN/AN/AN/ARENRESOLUTE ENERGY/SH NEWN/AN/AN/AN/AN/ALatest ASND, REN, EMH, PZG, and MRP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/16/2025MRPMillrose Propertiesquarterly$0.6910.04%7/3/20257/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71EMHEmerald Health Therapeutics35.452.972.61MRPMillrose Properties0.060.070.07PZGParamount Gold Nevada0.454.304.30RENRESOLUTE ENERGY/SH NEWN/A0.280.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AEMHEmerald Health TherapeuticsN/AMRPMillrose PropertiesN/APZGParamount Gold Nevada4.51%RENRESOLUTE ENERGY/SH NEWN/AInsider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%EMHEmerald Health TherapeuticsN/AMRPMillrose PropertiesN/APZGParamount Gold Nevada5.46%RENRESOLUTE ENERGY/SH NEW11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableMRPMillrose PropertiesN/A166.00 millionN/AN/APZGParamount Gold Nevada871.45 million67.55 millionNot OptionableRENRESOLUTE ENERGY/SH NEWN/A23.16 millionN/AOptionableASND, REN, EMH, PZG, and MRP HeadlinesRecent News About These CompaniesGeothermal power is vying to be a major player in the world’s clean-energy futureNovember 14, 2024 | nature.comNResolute Mining shares suspended in Australia as Mali government seeks $160MNovember 14, 2024 | msn.comResolute CEO still held in Mali, diplomatic sources say, as shares suspendedNovember 14, 2024 | reuters.comResolute Shares Suspended After Mali Demands $160 MillionNovember 14, 2024 | bloomberg.comAustralia's Resolute Mining confirms CEO and two other employees detained in MaliNovember 10, 2024 | reuters.comSam Altman-Backed Energy Stock Skyrockets Amid AI-Fueled Nuclear RenaissanceOctober 31, 2024 | msn.comHicks Acquisition’s Merger with Resolute Energy Corporation Approved by Stockholders and WarrantholdersAugust 19, 2024 | br.advfn.comResolute Energy Corporation Announces Closing of Business Combination with Hicks Acquisition Company I, Inc.August 19, 2024 | br.advfn.comNew Zealand’s Unique SpiritApril 12, 2024 | nationalgeographic.comNWhat’s new on Netflix and what’s leaving in April 2024April 2, 2024 | yahoo.comWhat’s Coming to Disney+ in April 2024March 29, 2024 | variety.comVPersonal FinanceFebruary 21, 2024 | foxbusiness.comWhat's New on the 2024-2025 FAFSAFebruary 14, 2024 | usnews.comGroton captain’s role in historic Resolute desksFebruary 11, 2024 | theday.comTAmazon Prime Video’s New Releases Coming in February 2024February 3, 2024 | hollywoodreporter.comHCheap Flights from Resolute to New York John F. KennedyNovember 27, 2023 | skyscanner.netSNew OpenAI CEO Emmett Shear says AI ‘doom’ risk ‘should cause you to s–t your pants’November 25, 2023 | nypost.comNBeyoncé Unleashes New ‘Renaissance’ Film Trailer Ahead of Theatrical RunNovember 13, 2023 | yahoo.comNew RenaissanceOctober 12, 2023 | outlookindia.com"Calm And Resolute": Japan Joins India, Others In Rejecting New China MapSeptember 17, 2023 | ndtv.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthNVIDIA’s Stock Price Hits New Highs: This Is What’s NextBy Thomas Hughes | June 26, 2025View NVIDIA’s Stock Price Hits New Highs: This Is What’s Next3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunTankers, Takedowns & Air Taxis: Insiders Are Buying These 3 NamesBy Leo Miller | June 10, 2025View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 NamesGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingASND, REN, EMH, PZG, and MRP Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$174.07 +0.97 (+0.56%) Closing price 02:42 PM EasternExtended Trading$174.07 0.00 (0.00%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Millrose Properties NYSE:MRP$28.03 -0.85 (-2.94%) As of 03:30 PM EasternMillrose Properties, Inc. is a real estate investment and management company that focuses on acquiring, developing, and managing high-quality commercial properties. They are headquartered in Purchase, New York.Paramount Gold Nevada NYSEAMERICAN:PZG$0.72 +0.04 (+6.27%) As of 05:00 PM EasternParamount Gold Nevada Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of precious metal properties in the United States. The company primarily explores for gold and silver deposits. It holds principal interest in the Sleeper gold project, which comprises 2,474 unpatented mining claims totaling approximately 44,917 acres located in Humbolt County, Nevada. The company also holds 100% interest in the Grassy Mountain gold project that consists of 455 unpatented lode claims, 3 patented lode claims, and 9 mill site claims covering an area of approximately 8,280 acres located in Malheur County, Oregon. In addition, it has an agreement to acquire 100% interests in the Frost Project, which consists of 40 mining claims located in Oregon; and the Bald Peak project located in Mineral County, Nevada. Paramount Gold Nevada Corp. was founded in 1992 and is headquartered in Winnemucca, Nevada.RESOLUTE ENERGY/SH NEW NYSE:RENResolute Energy Corporation, an independent oil and gas company, engages in the acquisition, exploitation, exploration for, and development of oil and gas properties in the United States. Its principal project area is located in the Delaware Basin portion of the Permian Basin, Reeves County. As of December 31, 2017, it had interests in approximately 27,100 gross acres located in the Permian Basin of Texas; and its estimated net proved reserves were approximately 53.4 million barrels of oil equivalent. Resolute Energy Corporation was founded in 2004 and is based in Denver, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
